Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rolapitant + Ondansetron for CINV in Malignant Glioma
NCT02991456Phase 2Completed
- Sponsor
- Duke University
- Start
- Oct 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rolapitant in chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), sponsored by Duke University. Started Oct 2017; status: completed.
02
Drugs
rolapitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)radiation-induced nausea and vomiting (RINV)
Beyond the preview
Go deeper on NCT02991456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991456.